These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 21982669)

  • 1. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT).
    McMurray JJ; Uno H; Jarolim P; Desai AS; de Zeeuw D; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; Parfrey P; Parving HH; Toto RM; Solomon SD; Pfeffer MA
    Am Heart J; 2011 Oct; 162(4):748-755.e3. PubMed ID: 21982669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill J; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R; Uno H;
    Am J Kidney Dis; 2009 Jul; 54(1):59-69. PubMed ID: 19501439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
    Mix TC; Brenner RM; Cooper ME; de Zeeuw D; Ivanovich P; Levey AS; McGill JB; McMurray JJ; Parfrey PS; Parving HH; Pereira BJ; Remuzzi G; Singh AK; Solomon SD; Stehman-Breen C; Toto RD; Pfeffer MA
    Am Heart J; 2005 Mar; 149(3):408-13. PubMed ID: 15864229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
    Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
    N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.
    Desai AS; Toto R; Jarolim P; Uno H; Eckardt KU; Kewalramani R; Levey AS; Lewis EF; McMurray JJ; Parving HH; Solomon SD; Pfeffer MA
    Am J Kidney Dis; 2011 Nov; 58(5):717-28. PubMed ID: 21820220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.
    Skali H; Parving HH; Parfrey PS; Burdmann EA; Lewis EF; Ivanovich P; Keithi-Reddy SR; McGill JB; McMurray JJ; Singh AK; Solomon SD; Uno H; Pfeffer MA;
    Circulation; 2011 Dec; 124(25):2903-8. PubMed ID: 22104547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
    Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
    N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
    Theilade S; Claggett B; Hansen TW; Skali H; Lewis EF; Solomon SD; Parving HH; Pfeffer M; McMurray JJ; Rossing P;
    J Hum Hypertens; 2016 Jan; 30(1):46-52. PubMed ID: 25810068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Mc Causland FR; Claggett B; Burdmann EA; Chertow GM; Cooper ME; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; McMurray JJV; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
    Am J Kidney Dis; 2019 Mar; 73(3):309-315. PubMed ID: 30578152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
    Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
    Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease.
    Weiner DE; Tighiouart H; Vlagopoulos PT; Griffith JL; Salem DN; Levey AS; Sarnak MJ
    J Am Soc Nephrol; 2005 Jun; 16(6):1803-10. PubMed ID: 15857925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Mc Causland FR; Claggett B; Burdmann EA; Eckardt KU; Kewalramani R; Levey AS; McMurray JJ; Parfrey P; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
    Am J Kidney Dis; 2016 Dec; 68(6):873-881. PubMed ID: 27646425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ischemic stroke history predicts increased cardiovascular mortality in chronic heart failure.
    Kozdağ G; Yaymacı M; Işeri P; Ertaş G; Emre E; Bildirici U; Kılıç T; Ural D
    Anadolu Kardiyol Derg; 2011 Aug; 11(5):421-7. PubMed ID: 21712170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
    Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
    Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
    Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
    Olsen MH; Wachtell K; Nielsen OW; Hall C; Wergeland R; Ibsen H; Kjeldsen SE; Devereux RB; Dahlöf B; Hildebrandt PR
    J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Charytan DM; Lewis EF; Desai AS; Weinrauch LA; Ivanovich P; Toto RD; Claggett B; Liu J; Hartley LH; Finn P; Singh AK; Levey AS; Pfeffer MA; McMurray JJ; Solomon SD
    Am J Kidney Dis; 2015 Sep; 66(3):429-40. PubMed ID: 25935581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.